Introduction Acute myocardial infarction (AMI) remains a leading cause of death in the
United States. The limited capacity of cardiomyocytes to regenerate and the restricted …

The therapeutic effects of stem cell transplantation in ischemic disease are mediated by the
production of paracrine bioactive factors. However, the bioactive factors secreted by human …

Therapy with mesenchymal stem cells is one of the promising tools to improve outcomes
after myocardial infarction. Adipose-derived stem cells (ASCs) are an ideal source of …

Background Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate
procedure of fat tissue and platelet rich plasma (PRP) can be obtained from peripheral …

Mesenchymal stem cells (MSC) are regarded as an attractive source of therapeutic stem
cells for myocardial infarction. However, their limited self-renewal capacity, low migration …

The limited efficacy of cardiac cell-based therapy is thought to be due to poor cell retention
within the myocardium. Hence, there is an urgent need for biomaterials that aid in long-term …

Cardiac tissue engineering promises to revolutionize the treatment of patients with end-
stage heart failure and provide new solutions to the serious problems of shortage of heart …

Adipose stem cells (ASCs) spheroids show enhanced regenerative effects compared to
single cells. Also, spheroids have been recently introduced as building blocks in directed …

Cardiac matrix hydrogel has shown great promise as an injectable biomaterial due to the
possession of cardiac-specific extracellular matrix composition. A cardiac matrix hydrogel …

Neurotrophins and the transplantation of bone marrow-derived stromal cells (MSCs) are
both candidate therapies targeting spinal cord injury (SCI). While some studies have …